SBIR/STTR Research Award

IMMUNE COMPLEXES (IC) PLAY AN IMPORTANT ROLE IN THE PATHOGENESIS OF CERTAIN HUMAN DISEASES, SUCH AS SERUM SICKNESS, GLOMERULONEPHITIDES, AND LUPUS ERYTHEMATOSUS, AND ARE ALSO ASSOCIATED WITH RHEUMATOID ARTHRITIS AND A VARIETY OF VASCULITIDES.

Award identifier 28903a1aeaa881642b10ac9678375213181c22950cc20489f76c49e374ccbc9eAwarding agency Department of Health and Human Services

Award amount

$72,851

Program and phase

SBIR · Phase I

Award year

1983

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
Not reported
Recipient company
Genetics Systems Corpon
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

IMMUNE COMPLEXES (IC) PLAY AN IMPORTANT ROLE IN THE PATHOGENESIS OF CERTAIN HUMAN DISEASES, SUCH AS SERUM SICKNESS, GLOMERULONEPHITIDES, AND LUPUS ERYTHEMATOSUS, AND ARE ALSO ASSOCIATED WITH RHEUMATOID ARTHRITIS AND A VARIETY OF VASCULITIDES. PRESENT TESTS FOR THE DETECTION OF IC RELYON PHYSIOCHEMICAL METHODS OR BIOLOGICALLY BASED ASSAYS WHICHSEPARATE IC FROM FREE ANTIBODY (AB). THE VARIOUS TESTS USEDDO NOT CORRELATE WELL WITH EACH OTHER, HAVE PROBLEMS IN THEIR SENSITIVITY AND/OR SPECIFICITY, AND DO NOT DISTINGUISHIC OF DIFFERENT IMMUNOGLOBULIN ISOTYPES OR SUBCLASSES. THERE IS A REAL NEED FOR A MORE SPECIFIC, SENSITIVE, AND EASY IC ASSAY FOR USE IN DIAGNOSIS, DETERMINING PROGNOSIS, AND MONITORING THERAPEUTIC INTERVENTION. WE PROPOSE TO DEVELOP MONOCLONAL ANTIBODIES (M.AB) SPECIFIC FOR IC WHICH DO NOT REACT WITH EITHER FREE ANTIGEN (AB) OR AB. THESE M.AB. MAY ENABLE IC OF DEFINED ISOTYPES TO BE DETECTED IN A HOMOGENEOUS ASSAY WITHOUT SEPARATION OF BOUND FROM UNBOUND AB. TO DEMONSTRATE THE FEASIBILITY OF THIS APPROACH, WE HAVE SELECTED A MURINE SYSTEM WITH WELL-DEFINED ANTIGENS (HAPTENS) AND WELL-DEFINED ANTIGEN OR HAPTEN-SPECIFIC ANTIBODIES OF DIFFERENT ISOTYPES. BOTH MONOVALENT HAPTEN (DINITROPHENOL, DNP) AND POLYVALENT DNA ANTIGENS WILL BE USED. FIRST, WE WILL DEVELOP M.AB WHICH REACT WITH HAPTEN- CARRIER-ANTIHAPTEN OR DNA-ANTI DNA IMMUNE COMPLEXES, BUT NOT WITH AG OR AB ALONE. SECOND, WE WILL DETERMINE IF ANY OF THE IC-SPECIFIC M.AB ARE SPECIFIC FOR CERTAIN ISOTYPES. THIRD, WE WILL DEMONSTRATE THAT THE EPITOPES RECOGNIZED BY THESE M.AB ARE DUE TO CONFORMATIONAL CHANGES IN THE BOUND ABAND NOT SIMPLY DUE TO AGGREGATION OR DIMER FORMATION. FINALLY, WE WILL BEGIN TO TEST THESE M.AB IN ASSAYS FOR IC IN SERA FROM MICE WITH AUTOIMMUNE DISEASE.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.